ASMB vs CRMD: stock comparison and AI forecast
Assembly Biosciences, Inc. (ASMB) and Cormedix Inc. (CRMD) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ASMB Assembly Biosciences, Inc.
- Price
- $20.86 -22.6% · 6M
- Market Cap
- $425M
- P/E Ratio
- 11.9x
- Size
- small-cap
- AI Forecast
- NO CURRENT FORECAST
CRMD Cormedix Inc.
- Price
- $5.70 -25.0% · 6M
- Market Cap
- $444M
- P/E Ratio
- 2.8x
- Size
- small-cap
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- ASMB and CRMD have similar market capitalizations ($425M and $444M).
- CRMD trades at 2.8 times trailing earnings, ASMB at 11.9 times.
- Over the last six months ASMB returned -22.6% and CRMD -25.0%.
- CRMD turns 41.4% of its revenue into net income, against -0.1% for ASMB.
- CRMD carries 0.96 times debt per unit of equity, against 0.08 times for ASMB.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ASMB | CRMD |
|---|---|---|
| Market Cap | $425M | $444M |
| P/E Ratio | 11.92x | 2.78x |
| P/B Ratio | 1.39x | 0.96x |
| EPS | $1.75 | $2.05 |
| Book Value/Share | $15.01 | $5.91 |
| Revenue/Share | $3.27 | $5.80 |
| FCF/Share | $-1.89 | $3.21 |
Profitability & Margins
| Metric | ASMB | CRMD |
|---|---|---|
| ROE | -0.0% | 40.6% |
| ROA | -0.0% | 20.7% |
| ROIC | -2.9% | 30.3% |
| Gross Margin | – | 90.0% |
| Operating Margin | -13.2% | 48.0% |
| Net Margin | -0.1% | 41.4% |
| EBT Margin | -5.5% | 45.0% |
| Tax Rate | 2.1% | 8.0% |
Financial Health
| Metric | ASMB | CRMD |
|---|---|---|
| Current Ratio | 13.99x | 2.56x |
| Quick Ratio | – | 2.36x |
| D/E Ratio | 0.08x | 0.96x |
| Financial Leverage | 1.08x | 1.96x |
| Interest Coverage | -0.8x | 15.2x |
| Working Capital | $305M | $293M |
Cash Flow
| Metric | ASMB | CRMD |
|---|---|---|
| Operating Cash Flow | -$38M | $254M |
| Free Cash Flow | -$39M | $250M |
| Capital Spending | -$90K | -$4M |
| OCF Growth YoY | – | 733.6% |
| FCF Growth YoY | – | 723.5% |
| FCF/Sales | -57.9% | 55.4% |
| CapEx/Sales | 0.1% | 0.8% |
Operational Efficiency
| Metric | ASMB | CRMD |
|---|---|---|
| Asset Turnover | 0.20x | 0.50x |
| Receivables Turnover | 81.1x | 2.8x |
| Inventory Turnover | – | 1.2x |
| Fixed Assets Turnover | 211.5x | 57.6x |
| Days Sales Outstanding | 4 days | 130 days |
| Days Inventory | – | 312 days |
| Payables Period | – | 83 days |
| Cash Conversion Cycle | – | 359 days |
Income Statement
| Metric | ASMB | CRMD |
|---|---|---|
| Total Revenue | $67M | $452M |
| Operating Income | -$9M | $217M |
| Net Income | -$40K | $187M |
| R&D Expense | $64M | $28M |
| SG&A Expense | – | $171M |
| Cost of Goods Sold | – | $45M |
Dividend & Shareholder Information
| Metric | ASMB | CRMD |
|---|---|---|
| Shares Outstanding | 20M | 78M |
| Net Income Growth | – | 265.9% |
| EPS Growth | – | 791.3% |
ASMB vs CRMD: stock comparison and AI forecast
Which is bigger, ASMB or CRMD?
ASMB and CRMD have similar market capitalizations ($425M and $444M).
Which is cheaper on earnings, ASMB or CRMD?
CRMD trades at 2.8 times trailing earnings, ASMB at 11.9 times.
Which stock performed better over the last six months, ASMB or CRMD?
Over the last six months ASMB returned -22.6% and CRMD -25.0%.
Which one does Intratio's AI model rank higher, ASMB or CRMD?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.